Clinical Trial Update: Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4) [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating optimal antithrombotic therapy for acute coronary syndrome patients with non-valvular atrial fibrillation who have received a ne…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Non-valvular Atrial Fibrillation

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Acute Coronary Syndrome (ACS), Non-valvular Atrial Fibrillation (NVAF) | Phase 4 | Status: UNKNOWN